BG
MLTX icon

Bellevue Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bellevue Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,052
Closed -$251K – 184
2025
Q3 		$251K Buy
35,052
+32,052
+1,068% +$1.67M 0.01% 130
2025
Q2 		$142K Hold
3,000
– – ﹤0.01% 132
2025
Q1 		$117K Sell
3,000
-1,400
-32% -$60.3K ﹤0.01% 139
2024
Q4 		$238K Hold
4,400
– – ﹤0.01% 140
2024
Q3 		$222K Hold
4,400
– – ﹤0.01% 145
2024
Q2 		$193K Hold
4,400
– – ﹤0.01% 149
2024
Q1 		$221K Buy
+4,400
New +$239K ﹤0.01% 152

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Bellevue Group's MLTX Position: Q4 2025 in Review

Bellevue Group sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 35,052 shares — an estimated $251K sold.

Bellevue Group first reported a position in MLTX in Q1 2024 and held it in 7 quarters. The position peaked at $251K in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Bellevue Group reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Bellevue Group sold 35,052 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $251K.
  • Bellevue Group first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 7 quarters.
  • Bellevue Group's MoonLake Immunotherapeutics position peaked at $251K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.